Volume 54, Issue 2, Pages (August 1998)

Slides:

Advertisements

Similar presentations

Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis Giuseppe D’Amico Kidney International Volume 54, Issue 2, Pages

Advertisements

A.M. Thompson, T.G. Pickering Kidney International

Volume 68, Issue 3, Pages (September 2005)

Eoin O’Brien, DSc, MD, Eamon Dolan, MD, FRCPI Clinical Therapeutics

Optimization of pre-ESRD care: The key to improved dialysis outcomes

Nina Vasavada, Rajiv Agarwal Kidney International

Management of IgA nephropathy: Evidence-based recommendations

Volume 54, Issue 2, Pages (August 1998)

Long-term evolution of cardiomyopathy in dialysis patients

Plasma sodium and hypertension

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Volume 70, Issue 3, Pages (August 2006)

Viper venom for diabetic nephropathy

Step Care Therapy for Hypertension in Diabetic Patients

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Angiotensin-converting enzyme gene polymorphism and risk of insulin resistance in PCOS Onder Celik, Elif Yesilada, Seyma Hascalik, Nilufer Celik, Ibrahim.

Prehypertension and chronic kidney disease: the ox or the plow?

Progression of renal failure and hypertensive nephrosclerosis

Volume 53, Issue 4, Pages (April 1998)

The myogenic response in uremic hypertension

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Volume 63, Issue 3, Pages (March 2003)

Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency Fiona E. Mackie, Timothy W. Meyer,

Homocysteine and risk in end-stage renal disease: a matter of context

Prediction of hypertension in chronic hemodialysis patients

Volume 54, Issue 5, Pages (November 1998)

Volume 74, Issue 3, Pages (August 2008)

Volume 72, Issue 12, Pages (December 2007)

The epidemiology of chronic kidney disease

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Volume 74, Issue 9, Pages (November 2008)

Volume 63, Issue 6, Pages (June 2003)

Elke Wühl, Otto Mehls, Franz Schaefer Kidney International

Volume 86, Issue 3, Pages (September 2014)

Blood pressure targets in hemodialysis patients

Volume 56, Issue 4, Pages (October 1999)

David M. Charytan, John P. Forman Kidney International

Volume 57, Issue 1, Pages (January 2000)

Volume 67, Issue 1, Pages (January 2005)

Volume 61, Issue 6, Pages (June 2002)

Volume 53, Issue 4, Pages (April 1998)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

The future of renoprotection: Frustration and promises

Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia

Long-term evolution of cardiomyopathy in dialysis patients

Volume 81, Issue 4, Pages (February 2012)

Volume 58, Issue 3, Pages (September 2000)

A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related.

Nina Vasavada, Chandan Saha, Rajiv Agarwal Kidney International

Volume 58, Issue 5, Pages (November 2000)

Volume 64, Issue 2, Pages (August 2003)

A coding polymorphism in the 12-lipoxygenase gene is associated to essential hypertension and urinary 12(S)-HETE L.F. Quintana, B. Guzmán, S. Collado,

Carmine Zoccali, Francesca Mallamaci Kidney International

Volume 73, Issue 5, Pages (March 2008)

Nina Vasavada, Rajiv Agarwal Kidney International

David Z. Levine, M.D., Michelle Iacovitti, Kevin D. Burns, Amy Slater

Volume 63, Issue 4, Pages (April 2003)

Volume 68, Issue 5, Pages (November 2005)

Volume 57, Issue 3, Pages (March 2000)

Volume 75, Issue 1, Pages (January 2009)

Importance of blood pressure control in hemodialysis patient survival

Does an apple a day put hypertension in play?

Erratum Kidney International Volume 61, Issue 4, (April 2002)

Volume 68, Issue 3, Pages (September 2005)

Optimization of pre-ESRD care: The key to improved dialysis outcomes

Volume 60, Issue 2, Pages (August 2001)

Antonio Piccoli, Luana Pillon Kidney International

Presentation transcript:

Volume 54, Issue 2, Pages 618-626 (August 1998) Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy Giuseppe Cannella, Ernesto Paoletti, Sergio Barocci, Fabio Massarino, Roberto Delfino, Giambattista Ravera, Giovanni Di Maio, Arcangelo Nocera, Pietro Patrone, Davide Rolla Kidney International Volume 54, Issue 2, Pages 618-626 (August 1998) DOI: 10.1046/j.1523-1755.1998.00027.x Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 1 Changes of left ventricular mass indices plotted against corresponding changes in systolic blood pressures occurring after five years on continuous antihypertensive therapy in 30 chronically hemodialyzed uremics (r = 0.37; P = 0.044). Kidney International 1998 54, 618-626DOI: (10.1046/j.1523-1755.1998.00027.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 2 Values (mean ± sem) of 24-hour monitored systolic (S) and diastolic (D) blood presures (BP) and left ventricular mass indices (LVMi) for groups of hypertensive hemodialyzed uremics bearing the DD (•; N = 13) or II/ID (○; N = 17) ACE-gene genotype while on continuous antihypertensive therapy that included ACE inhibitors. Asterisks indicate the time at which a significant difference was detectable with respect to the basal value. Kidney International 1998 54, 618-626DOI: (10.1046/j.1523-1755.1998.00027.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 3 Percent changes for the left ventricular mass indices after five years on a continuous antihypertensive therapy, which included ACE inhibitors, for 30 hemodialyzed uremics bearing different ACE-gene genotype (• DD; ID; ○ II). The “F” value for possible differences among groups, by ANOVA, is indicated. Kidney International 1998 54, 618-626DOI: (10.1046/j.1523-1755.1998.00027.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 618-626DOI: (10. 1046/j. 1523-1755. 1998 Kidney International 1998 54, 618-626DOI: (10.1046/j.1523-1755.1998.00027.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 618-626DOI: (10. 1046/j. 1523-1755. 1998 Kidney International 1998 54, 618-626DOI: (10.1046/j.1523-1755.1998.00027.x) Copyright © 1998 International Society of Nephrology Terms and Conditions